Tvardi Therapeutics (TVRD) Competitors $27.34 +4.67 (+20.60%) As of 07/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock TVRD vs. GHRS, REPL, SNDX, XERS, VIR, CRON, OCS, CMRX, CRMD, and QUREShould you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include GH Research (GHRS), Replimune Group (REPL), Syndax Pharmaceuticals (SNDX), Xeris Biopharma (XERS), Vir Biotechnology (VIR), Cronos Group (CRON), Oculis (OCS), Chimerix (CMRX), CorMedix (CRMD), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Tvardi Therapeutics vs. Its Competitors GH Research Replimune Group Syndax Pharmaceuticals Xeris Biopharma Vir Biotechnology Cronos Group Oculis Chimerix CorMedix uniQure Tvardi Therapeutics (NASDAQ:TVRD) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Does the media favor TVRD or GHRS? In the previous week, Tvardi Therapeutics had 3 more articles in the media than GH Research. MarketBeat recorded 8 mentions for Tvardi Therapeutics and 5 mentions for GH Research. Tvardi Therapeutics' average media sentiment score of 0.56 beat GH Research's score of 0.29 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend TVRD or GHRS? Tvardi Therapeutics currently has a consensus price target of $65.00, suggesting a potential upside of 137.75%. GH Research has a consensus price target of $32.00, suggesting a potential upside of 101.64%. Given Tvardi Therapeutics' higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, TVRD or GHRS? GH Research has lower revenue, but higher earnings than Tvardi Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTvardi Therapeutics$7.14M35.84-$70.87MN/AN/AGH ResearchN/AN/A-$38.96M-$0.79-20.09 Do institutionals & insiders hold more shares of TVRD or GHRS? 44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by insiders. Comparatively, 41.6% of GH Research shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is TVRD or GHRS more profitable? GH Research has a net margin of 0.00% compared to Tvardi Therapeutics' net margin of -595.39%. GH Research's return on equity of -19.20% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics-595.39% -710.04% -79.00% GH Research N/A -19.20%-18.40% Which has more risk and volatility, TVRD or GHRS? Tvardi Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. SummaryGH Research beats Tvardi Therapeutics on 8 of the 12 factors compared between the two stocks. Get Tvardi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricTvardi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.90M$2.93B$5.54B$9.08BDividend YieldN/A2.43%5.06%4.03%P/E RatioN/A20.9928.2820.33Price / Sales35.84251.49411.8596.42Price / CashN/A41.0526.2427.98Price / Book-9.057.638.125.50Net Income-$70.87M-$55.05M$3.19B$250.38M7 Day Performance27.04%7.11%3.68%2.19%1 Month Performance11.05%8.14%7.69%10.92%1 Year PerformanceN/A1.62%29.35%16.41% Tvardi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDTvardi TherapeuticsN/A$27.34+20.6%$65.00+137.7%N/A$255.90M$7.14M0.0080News CoverageAnalyst ForecastAnalyst RevisionGap UpGHRSGH Research1.9697 of 5 stars$15.87-1.1%$32.00+101.6%+32.4%$835.05MN/A-20.0910REPLReplimune Group4.1554 of 5 stars$10.97+1.9%$20.83+89.9%+5.9%$830.22MN/A-3.57210High Trading VolumeSNDXSyndax Pharmaceuticals3.1418 of 5 stars$9.59-2.3%$34.30+257.7%-59.2%$825.19M$43.72M-2.48110XERSXeris Biopharma3.9666 of 5 stars$5.11-3.0%$6.25+22.3%+117.0%$824.15M$203.07M-17.03290VIRVir Biotechnology3.591 of 5 stars$5.65-4.7%$30.25+435.4%-39.7%$819.75M$74.21M-1.34580Analyst UpgradeCRONCronos Group1.5733 of 5 stars$2.09-0.5%N/A-13.3%$809.93M$117.61M16.08450OCSOculis2.0796 of 5 stars$18.06-1.8%$35.33+95.6%+58.7%$803.39M$780K-6.842CMRXChimerix0.5528 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CRMDCorMedix2.5531 of 5 stars$11.22-4.2%$17.14+52.8%+134.7%$794.23M$43.47M51.0030QUREuniQure2.555 of 5 stars$14.40-3.2%$37.82+162.6%+65.1%$788.77M$20.20M-3.28500 Related Companies and Tools Related Companies GH Research Alternatives Replimune Group Alternatives Syndax Pharmaceuticals Alternatives Xeris Biopharma Alternatives Vir Biotechnology Alternatives Cronos Group Alternatives Oculis Alternatives Chimerix Alternatives CorMedix Alternatives uniQure Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
